Tumor Cell-Derived TGFβ1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA
Related Experiment Video
Updated: Dec 7, 2025
Pengfei Wu1,2, Bo Geng1, Qun Chen3
1Department of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Abstract:
Dysfunction in T-cell antitumor activity contributes to the tumorigenesis, progression, and poor outcome of clear cell renal cell carcinoma (ccRCC), with this dysfunction resulting from high expression of programmed cell death-1 (PD-1) in T cells. However, the molecular mechanisms maintaining high PD-1 expression in T cells have not been fully investigated in ccRCC. Here, we describe a mechanism underlying the regulation of PD-1 at the mRNA level and demonstrated its impact on T-cell dysfunction. Transcriptomic analysis identified a correlation between TGFβ1 and PD-1 mRNA levels in ccRCC samples. The mechanism underlying the regulation of PD-1 mRNA was then investigated in vitro and in vivo using syngeneic tumor models. We also observed that TGFβ1 had prognostic significance in patients with ccRCC, and its expression was associated with PD-1 mRNA expression. CcRCC-derived TGFβ1 activated P38 and induced the phosphorylation of Ser10 on H3, which recruited p65 to increase SRSF3 and SRSF5 expression in T cells. As a result, the half-life of PD-1 mRNA in T cells was prolonged. SRSF3 coordinated with NXF1 to induce PD-1 mRNA extranuclear transport in T cells. We then demonstrated that TGFβ1 could induce SRSF3 expression to restrict the antitumor activity of T cells, which influenced immunotherapy outcomes in ccRCC mouse models. Our findings highlight that tumor-derived TGFβ1 mediates immune evasion and has potential as a prognostic biomarker and therapeutic target in ccRCC.See related Spotlight on p. 1464.
Insights
Tumor-derived TGFβ1 increases PD-1 mRNA in T cells, hindering antitumor activity in clear cell renal cell carcinoma (ccRCC). This mechanism offers a potential therapeutic target for ccRCC immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- T-cell dysfunction, marked by high programmed cell death-1 (PD-1) expression, drives clear cell renal cell carcinoma (ccRCC) progression.
- The precise molecular mechanisms sustaining PD-1 elevation in ccRCC T cells remain incompletely understood.
Purpose of the Study:
- To elucidate the molecular mechanisms regulating PD-1 expression at the mRNA level in ccRCC.
- To investigate the functional impact of these mechanisms on T-cell dysfunction and antitumor activity.
Main Methods:
- Transcriptomic analysis of ccRCC samples to identify correlations between TGFβ1 and PD-1 mRNA.
- In vitro and in vivo investigations using syngeneic tumor models to study PD-1 mRNA regulation.
- Analysis of TGFβ1's prognostic significance and its association with PD-1 mRNA expression.
Main Results:
- A correlation between TGFβ1 and PD-1 mRNA levels was identified in ccRCC.
- TGFβ1 activates P38 and H3 phosphorylation, leading to increased SRSF3/SRSF5 expression in T cells, prolonging PD-1 mRNA half-life.
- SRSF3 facilitates PD-1 mRNA export, and TGFβ1-induced SRSF3 restricts T-cell antitumor activity, impacting immunotherapy outcomes in mouse models.
Conclusions:
- Tumor-derived TGFβ1 promotes immune evasion in ccRCC by upregulating PD-1 expression in T cells.
- TGFβ1 serves as a potential prognostic biomarker and therapeutic target for ccRCC.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Tumor Immunotherapy
TGF - β Signaling Pathway
The Tumor Microenvironment
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Mitogens and the Cell Cycle


